{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T03:37:16Z","timestamp":1769312236245,"version":"3.49.0"},"reference-count":19,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T00:00:00Z","timestamp":1760832000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["accp1.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Pharm in Drug Dev"],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Fezolinetant is a non\u2010hormonal, selective neurokinin\u20103 receptor antagonist that blocks neurokinin B activation of kisspeptin\/neurokinin B\/dynorphin neurons to thereby modulate neuronal activity in the thermoregulatory center. Fezolinetant has been approved in many regions, including North America, Europe, Asia, and Australia for the treatment of vasomotor symptoms associated with menopause at a dose of 45\u00a0mg once daily (QD). The risk of potential QT prolongation for fezolinetant was assessed prior to the initiation of the phase 3 trials. A concentration\u2013QTc (C\u2013QTc) analysis was performed in accordance with recommendations from ICH E14 Guideline and utilized data from a phase 1 single and multiple ascending dose study, which tested single doses up to 900\u00a0mg and multiple daily doses up to 720\u00a0mg in healthy male and female participants. The fezolinetant C\u2013QTc relationship indicated no clinically relevant QT prolongation at therapeutic or supra\u2010therapeutic doses of fezolinetant. Based on these modeling results as well as data from other clinical and non\u2010clinical studies, no thorough QT\/QTc (TQT) study was required for fezolinetant.<\/jats:p>","DOI":"10.1002\/cpdd.1613","type":"journal-article","created":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T14:42:20Z","timestamp":1760884940000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Concentration\u2013QTc Modeling to Support Clinical Development of Fezolinetant"],"prefix":"10.1002","volume":"15","author":[{"given":"Jace C.","family":"Nielsen","sequence":"first","affiliation":[{"name":"Astellas Pharma Global Development, Inc.  IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Saito","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xuegong","family":"Wang","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc.  IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megumi","family":"Iwai","sequence":"additional","affiliation":[{"name":"Astellas Pharma, Inc.  Tokyo Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graeme L.","family":"Fraser","sequence":"additional","affiliation":[{"name":"Ogeda SA  Gosselies Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Ramael","sequence":"additional","affiliation":[{"name":"Ogeda SA  Gosselies Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiayin","family":"Huang","sequence":"additional","affiliation":[{"name":"Astellas Pharma Global Development, Inc.  IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,10,19]]},"reference":[{"key":"e_1_2_10_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yfrne.2013.07.003"},{"key":"e_1_2_10_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2015-1409"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1097\/GME.0000000000001510"},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00085-5"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgad058"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.1097\/AOG.0000000000005114"},{"key":"e_1_2_10_8_1","unstructured":"VEOZAH\u00ae(fezolinetant) tablets for oral use.Highlights of prescribing information.2024.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/216578s004lbl.pdf"},{"key":"e_1_2_10_9_1","unstructured":"PrVEOZAH\u00ae;fezolinetant tablets; tablet 45\u00a0mg oral; other gynecologicals (G02CX06).Product monograph: including patient medication information.2024. Accessed April 24 2025.https:\/\/pdf.hres.ca\/dpd_pm\/00077931.PDF"},{"key":"e_1_2_10_10_1","unstructured":"Veoza 45\u00a0mg film\u2010coated tablets annex i: summary of product characteristics.2023. Accessed April 24 2025.https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/veoza\u2010epar\u2010product\u2010information_en.pdf"},{"key":"e_1_2_10_11_1","unstructured":"Veoza 45\u00a0mg film\u2010coated tablets summary of product characteristics.2025. Accessed April 24 2025.https:\/\/mhraproducts4853.blob.core.windows.net\/docs\/e6b1f8b85b2a5341888c20a91f33d0d51894054b"},{"key":"e_1_2_10_12_1","unstructured":"Veoza\u2122.2025. Accessed April 24 2025.https:\/\/ndi.fda.moph.go.th\/uploads\/drug_detail_corporation\/doc\/word\/1263\/7c4b97727e0e458e6b8908689db94332\u2010a1.pdf"},{"key":"e_1_2_10_13_1","unstructured":"Australian product information \u2010 VEOZA\u2122 (fezolinetant).2024. Accessed April 24 2025.https:\/\/www.ebs.tga.gov.au\/ebs\/picmi\/picmirepository.nsf\/pdf?OpenAgent=&id=CP\u20102024\u2010PI\u201001388\u20101&d=20240314172310101"},{"key":"e_1_2_10_14_1","unstructured":"ICH E14 Guideline.2005.The Clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs.http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_Guideline.pdf"},{"key":"e_1_2_10_15_1","unstructured":"ICH E14 Guideline.2015.The clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non\u2010antiarrhythmic drugs. Questions & answers (R3).http:\/\/www.ich.org\/fileadmin\/Public_Web_Site\/ICH_Products\/Guidelines\/Efficacy\/E14\/E14_Q_As_R3__Step4.pdf"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-017-9558-5"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6157"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-012-9292-y"},{"key":"e_1_2_10_19_1","unstructured":"FDA.Summary basis of approval. Non\u2010clinical review.2023. Accessed April 24 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/216578Orig1s000PharmR.pdf."},{"key":"e_1_2_10_20_1","unstructured":"FDA.Summary basis of approval. Clinical review. Accessed April 24 2025.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2023\/216578Orig1s000MedR.pdf"}],"container-title":["Clinical Pharmacology in Drug Development"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1613","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cpdd.1613","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpdd.1613","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T14:23:15Z","timestamp":1769264595000},"score":1,"resource":{"primary":{"URL":"https:\/\/accp1.onlinelibrary.wiley.com\/doi\/10.1002\/cpdd.1613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,19]]},"references-count":19,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1002\/cpdd.1613"],"URL":"https:\/\/doi.org\/10.1002\/cpdd.1613","archive":["Portico"],"relation":{},"ISSN":["2160-763X","2160-7648"],"issn-type":[{"value":"2160-763X","type":"print"},{"value":"2160-7648","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,19]]},"assertion":[{"value":"2025-06-23","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-15","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-19","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e1613"}}